BioSpace News Archive

Numinus Wellness Inc. (TSX: NUMI) is pleased to announce that Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an investigational new therapy for treatment-resistant depression (TRD), as part of the largest-ever international clinical study of psilocybin therapy.

Castle Biosciences, Inc. recognizes the importance of Skin Cancer Awareness Month and is proud to continue its ongoing collaboration with The Sun Bus and The Skin Cancer Foundation in support of skin cancer prevention, research, education and advocacy.

BeiGene, Ltd. announced today that BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor (BTKi), has been approved by Health Canada for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

Abstract published online in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings.

Genprex, Inc. today announced that it has completed the Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC), and the Safety Review Committee (SRC) has approved continuation to the Phase 2 expansion portion of the trial.

Palatin Technologies, Inc. today announced the presentation of the poster “MC1R Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced Rat Model of Diabetic Nephropathy” at the International Podocyte Conference May 24-26, 2023 in Philadelphia, PA.

Immuneering Corporation today announced that management will present at the Jefferies Healthcare Conference to discuss the company’s pipeline, platform, and business strategy.

908 Devices Features its High-Speed, High-Resolution Separations Technology at the 71st ASMS Conference.

Akebia Therapeutics®, Inc. today announced that the company received a written response from the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) to Akebia’s Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) received in March 2022 for vadadustat.

Galecto, Inc. announced that Hans Schambye, M.D., Ph.D. will present at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.